Somnomed Ltd
ASX:SOM
Somnomed Ltd
ASX:SOM
Price:
0.25 AUD
16.28%
Market Closed
Updated:
May 14, 2024
P/E
Price to Earnings
Price to Earnings
-2.6
Current
-31.3
Median
23.9
Industry
Higher
than median
Lower
than industry value
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
P/E
=-2.6
Market Cap
/
27.1m
Net Income
-10.6m
All Countries
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| AU |
|
Somnomed Ltd
ASX:SOM
|
27.1m AUD | -2.6 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
182.3B USD | 32.4 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
135.1B USD | 68 | |
| US |
|
Stryker Corp
NYSE:SYK
|
123.6B USD | 36.8 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
111.1B USD | 26.4 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
107B USD | 60.6 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
68.5B USD | 56.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
58.8B EUR | 38.8 | |
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
374.7B CNY | 30.8 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
51B USD | 36.1 | |
| US |
|
Dexcom Inc
NASDAQ:DXCM
|
49.5B USD | 77.4 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/E
-4.3
2-Years Forward
P/E
-16.5
3-Years Forward
P/E
-123.8
You don't have any saved screeners yet
